VE303 to prevent repeat C. diff infections
Part of Digestive system, Infections clinical trials.
This trial tests a new medicine called VE303, a live bacterial therapy, to prevent C. diff infections from coming back. It is for people who have had C. diff at least once in the last 6 months, or who are at high risk for a repeat infection due to age or other health problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had a lab-confirmed C. diff infection (with at least 3 loose stools in 24 hours on two days) within the last 6 weeks, and you completed standard antibiotics
- You either had another C. diff infection in the last 6 months, OR you are 75+ years old, OR you have 2 or more risk factors like age over 65, kidney problems, recent PPI use, prior C. diff 6–12 months ago, a weak immune system, or transplant history
- Your C. diff symptoms are now under control (less than 3 loose stools per day) for at least 2 days
- You have no chronic diarrhea from other causes, no active inflammatory bowel disease or other serious gut conditions (like celiac disease, microscopic colitis, short gut, or recent bowel ischemia)
- You have not used bezlotoxumab (Zinplava) for this current C. diff episode, and you won't need other antibiotics for a non-CDI infection through Week 24
- You can stop probiotics (yogurt and kefir are okay) 2 days before study drug and during dosing
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at levels of C. diff toxins in stool after standard antibiotic treatment. It aims to understand how toxins change during recovery, which may help improve future treatments for C. diff infections.
This study tests a new live bacteria product (EXL01) given with vancomycin to prevent C. diff from coming back. It is for people who have already had C. diff two or more times and are at high risk of another infection.
This study tests a new antibody (AZD5148) to prevent C. diff infection from coming back. If you have a current C. diff infection and are being treated with antibiotics, you may be able to join.
This study tests whether specific lifestyle changes during treatment for C. difficile infection (a serious gut bacteria infection) can help prevent it from coming back. You'll receive standard antibiotic treatment and follow a controlled diet while researchers track your recovery.
This trial tests whether taking vancomycin by mouth can prevent another C. diff infection when you need to take other antibiotics. It’s for patients who recently had C. diff and are about to start a new antibiotic course.
This trial tests whether adding a bile acid supplement (ursodeoxycholic acid) to standard antibiotics can help prevent a repeat C. diff infection. It is for people who have already had a C. diff infection and have at least one factor that increases their risk of it coming back.
Hear when a new Clostridium Difficile trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.